Delivery Order SPE2DB25D3404-SPE2DB25FUNUY
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of TEZSPIRE 210 mg/1.91 mL pen injectors. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation and represents a standard...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $7,030.77 for TEZSPIRE 210 mg/1.91 mL pen injectors, with a completion date of August 4, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 ml pen auto-injectors on September 3, 2025, with an ultimate completion date of September 24, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen auto-injectors on June 2, 2025, with completion scheduled for June 24, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical procurement and holds a significant role in supporting military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors. This competitive award, issued on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed-price transaction under a non-set-aside procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a $14,061.54 firm fixed price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors with completion targeted for October 9, 2025. This non-set-aside competitive award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement, particularly for military and veteran healthcare systems. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injections on August 5, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of August 26, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a small-value transaction...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of TEZSPIRE 210 mg/1.91 mL pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of May 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pen injectors. This is a firm fixed price, competitively awarded order with no set-aside designation. The contract is a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a maximum value of $999,999,999.00 through December 2026. Performance will be completed by August...
- The Defense Logistics Agency (DLA) awarded a $4,687.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors, with an ultimate completion date of August 26, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUNUYDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,717.95 to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injections, with performance completion scheduled for July 7, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order represents a task under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply medications, vaccines, and medical supplies to support military healthcare programs worldwide. TEZSPIRE is a specialty biologic medication used for severe eosinophilic asthma treatment, consistent with AmerisourceBergen's portfolio of delivering specialized therapeutic medications across multiple disease states to Defense Health Agency and U.S. Coast Guard customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.7k | 6/12/25 |